Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | MTHFD2 | P13995 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | APEX1 | P27695 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 2/20 | 0.34 |
| ▸ | SLC27A1 | Q6PCB7 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13772455 | 0.76 | HSD17B10 (0.60) | MAPK1HTTHSD17B10KMT2AMEN1 | |
| SCHEMBL29876882 | 0.75 | MEN1 (0.40) | MAPK1HTTHSD17B10KMT2AMEN1 | |
| SCHEMBL23931135 | 0.70 | HSD17B10 (0.47) | MAPK1HTTHSD17B10KMT2AMEN1 | |
| SCHEMBL24656125 | 0.70 | MEN1 (0.35) | MAPK1KMT2AMEN1HDAC6ALDH1A1 | |
| SCHEMBL24079283 | 0.69 | MAPK1 (0.40) | MAPK1HTTHSD17B10KMT2AMEN1 | |
| SCHEMBL24517708 | 0.66 | HTT (0.51) | HTTKMT2APOLBTP53SMN1; SMN2 | |
| SCHEMBL19909627 | 0.66 | MAPK1 (0.43) | MAPK1HTTHSD17B10KMT2AMEN1 | |
| SCHEMBL28626993 | 0.66 | MAPK1 (0.40) | MAPK1HTTHSD17B10KMT2AMEN1 | |
| SCHEMBL28470543 | 0.66 | MAPK1 (0.40) | MAPK1HTTHSD17B10KMT2AMEN1 | |
| SCHEMBL13041017 | 0.65 | MAPK1 (0.64) | MAPK1HTTHSD17B10KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12577243-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2026-03-17 | — | — | US | disclosed |
| EP-3856178-B1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2026-03-11 | — | — | EP | disclosed |
| CN-114423758-B | Antibacterial compounds | 爱尔兰詹森科学公司 | 2025-05-27 | — | — | CN | disclosed |
| CN-113164459-B | Monoacylglycerol lipase modulators | 詹森药业有限公司 | 2024-09-03 | — | — | CN | disclosed |
| US-20240199611-A1 | ANTIBACTERIAL COMPOUNDS | Janssen Sciences Ireland Unlimited Company (IE) | 2024-06-20 | — | — | US | disclosed |
| EP-4028399-B1 | ANTIBACTERIAL COMPOUNDS | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2024-02-14 | — | — | EP | disclosed |
| EP-4308239-A1 | ANTIBACTERIAL COMPOUNDS | Janssen Sciences Ireland Unlimited Company (IE) | 2024-01-24 | — | — | EP | disclosed |
| CN-117396475-A | Antibacterial compounds | 爱尔兰詹森科学公司 | 2024-01-12 | — | — | CN | disclosed |
| US-11820766-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-21 | — | — | US | disclosed |
| US-20230145249-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-11 | — | — | US | disclosed |
| WO-2023073090-A1 | IMIDAZOPYRIDINE AMIDES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF BACTERIAL INFECTIONS | Janssen Sciences Ireland Unlimited Company (IE) | 2023-05-04 | — | — | WO | disclosed |
| US-20220340564-A1 | ANTIBACTERIAL COMPOUNDS | JANSSEN-CILAG (FR) | 2022-10-27 | — | — | US | disclosed |
| US-20220332713-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2022-10-20 | — | — | US | disclosed |
| WO-2022194803-A1 | ANTIBACTERIAL COMPOUNDS | Janssen Sciences Ireland Unlimited Company (IE) | 2022-09-22 | — | — | WO | disclosed |
| EP-4028399-A1 | ANTIBACTERIAL COMPOUNDS | Janssen Sciences Ireland Unlimited Company (IE) | 2022-07-20 | — | — | EP | disclosed |
| CN-114423758-A | Antibacterial compounds | 爱尔兰詹森科学公司 | 2022-04-29 | — | — | CN | disclosed |
| EP-3856178-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | Janssen Pharmaceutica NV (BE) | 2021-08-04 | — | — | EP | disclosed |
| WO-2021048342-A1 | ANTIBACTERIAL COMPOUNDS | Janssen Sciences Ireland Unlimited Company (IE) | 2021-03-18 | — | — | WO | disclosed |
| WO-2020065613-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-04-02 | — | — | WO | disclosed |
| US-20200102303-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2020-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220332713-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | MAPK1 4389/4885HTT 3293/4885HSD17B10 120/4885 |
| US-20240199611-A1 | ANTIBACTERIAL COMPOUNDS | FDPS, MT-ND4, NDUFS3 | MAPK1 3767/4885HTT 3396/4885HSD17B10 2327/4885 |
| US-12577243-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, FAAH | MAPK1 4010/4885HTT 3651/4885HSD17B10 146/4885 |
| US-20200102303-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | MAPK1 4389/4885HTT 3293/4885HSD17B10 120/4885 |
| US-20230145249-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | MAPK1 4389/4885HTT 3293/4885HSD17B10 120/4885 |
| US-20220340564-A1 | ANTIBACTERIAL COMPOUNDS | FDPS, SQOR, NDUFS3 | MAPK1 3763/4885HTT 3111/4885HSD17B10 1973/4885 |
| US-11820766-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | MAPK1 4389/4885HTT 3293/4885HSD17B10 120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.